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Introduction
Emphysema is a common, debilitating pulmonary condi-
tion, the impact of which is felt worldwide, placing an
enormous economic strain on international health care
infrastructures. In the UK, data from 1996 indicate that the
medical cost of chronic obstructive pulmonary disease
(COPD) was approximately £846 million or about £1154
per person per year [1]. In the USA, over 106,000 people
die from COPD yearly making it the fourth leading cause
of death nationwide [2]. Moreover, while death rates for
heart disease and stroke have declined by roughly 50%
over the past 30 years, the death rate for COPD has risen
by 71% [2]. In 1993, it was estimated that 14.7 billion
dollars were spent in the USA on direct COPD-related
health care expenditures, costing roughly the equivalent of
£764 per person per year [1]. As the life expectancy of
the populations of industrialized nations continues to
increase, it is certain that the costs of emphysema in terms
of lives lost and strains on limited health care resources
will continue to grow.
Elastase/anti-elastase hypothesis
In light of these statistics on the global impact of this
disease, it is surprising to realize that even the basic
pathophysiology of emphysema is still being debated.
While it is clearly established that cigarette smoke is the
principal cause of emphysema, the mechanism by which
cigarette smoke exposure leads to the destruction of lung
architecture seen in emphysema is controversial. Elastin is
an important component of the extracellular matrix (ECM)
that is believed to confer upon the lung the resilience
needed to undergo repetitive physiologic stress. For over
30 years, the leading hypothesis has been that emphy-
sema resulted from an elastase/anti-elastase imbalance.
This theory was formulated after it was noted that smokers
with a congenital deficiency of alpha-1-antitrypsin (α1-AT)
had an excessive incidence of emphysema [3]. Given the
increased neutrophil content seen in the lungs of smokers
and the fact that α1-AT inactivates neutrophil elastase, it
was believed that elastin degradation via neutrophil elas-
tase was the pivotal factor responsible for the develop-
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ment of emphysema. The finding that the intratracheal
administration of papain, a powerful elastase, could lead
to the formation of emphysematous alveoli in the lungs of
experimental animals further supported this elastin-based
model of disease. These two findings have led to the
widespread and persistent acceptance of the elastase/
anti-elastase imbalance theory.
Recently, investigators have questioned the elastin-based
model of disease for several reasons. Not all patients with
congenital deficiency of α1-AT who smoke will develop
emphysema, and patients who have a partial deficiency do
not have an increased risk of emphysema [4]. While nearly
all smokers have accumulation of neutrophils in their
lungs, only a small minority develop emphysematous
changes, and neutrophil number does not correlate with
parenchymal destruction in the disease [5]. Studies to
date have also failed to demonstrate elastase excess or
inhibitor deficiency in smoking-induced emphysema [6,7].
Despite these reservations, the contribution of neutrophil
elastase to emphysema pathogenesis cannot be ignored.
Importantly, the survival time of the neutrophil in the lung is
very brief, lasting only a few hours. Thus, studies examin-
ing a single time-point in the course of a prolonged
disease may easily underestimate the true impact of this
cell type in pathogenesis. Furthermore, a lack of elastase
excess does not preclude that significant elastin degrada-
tion is occurring. Several investigators have shown that
the concentration of elastase at the site of release from
the azurophilic granule is supraphysiological and, thus,
cannot be inhibited by even normal concentrations of
inhibitors [8,9]. Campbell and colleagues have demon-
strated that elastase enzyme-inhibitor kinetics do not
follow a linear pattern. Rather, after inhibitor levels fall
below a certain threshold, proteolytic bursts can occur in
an exponential fashion [8]. This may explain why patients
with a partial deficiency of α1-AT do not develop emphy-
sema. Although elastase does not represent the mecha-
nism for all emphysema, there is still a role for this enzyme
in the disease process. It is important to realize that multi-
ple factors are involved in the pathogenesis of emphysema
[10] and no single agent will be totally responsible for the
pathology seen in this disease.
Studies performed on a metalloelastase (matrix metallo-
proteinase [MMP]-12)-knockout mouse recently provided
support for the involvement of elastolytic enzymes in
emphysema [11]. These mice do not express the MMP-12
gene and have a normal lung phenotype. When the
animals are exposed to cigarette smoke they do not
develop emphysematous changes in the lung as wild-type
animals do [11]. This study demonstrates that the
macrophage is crucial to the development of emphysema
in the mouse smoking model since, in the absence of
these cells, emphysema does not develop. There is no
direct evidence, however, which demonstrates that excess
activity of MMP-12 is involved in the human disease. In
fact, experiments examining human alveolar macrophages
and lung tissue from patients with emphysema and from
normal volunteers did not demonstrate increased levels of
MMP-12 in the patients with emphysema in either site
[12,13]. The lack of MMP-12 involvement in the human
disease, therefore, may be accounted for by the fact that
rodent and human macrophages differ significantly in their
repertoire of MMPs [14].
Collagen degradation
Fibrillar collagen, another component of the ECM, is vital
for maintaining the normal lung architecture. Type I colla-
gen, in fact, is the major structural element of the lung,
comprising 50–60% of the ECM [15]. Histological studies
have demonstrated that fibrils from type I and III collagen
are widely distributed in the lung. They are present in the
adventitia of pulmonary arteries, the interstitium of the
bronchial tree, the interlobular septa, the bronchial lamina
propria and the alveolar interstitium, where the pathologi-
cal changes of emphysema are known to occur. There are
a number of correlative studies which suggest that colla-
genase, a classical member of the MMP family which
degrades the fibrillar collagens, may be involved in several
lung diseases [16,17]. In addition, studies suggest that
collagen is degraded or damaged in pulmonary emphy-
sema, for example, antibodies to collagen have been
found in the serum of patients with emphysema [18].
Emphysematous changes have also been reported in
patients with the inherited disorder, type VI Ehlers-Danlos
syndrome, which causes a decreased structural integrity
of collagen fibrils [19]. It has also been shown that colla-
gen is affected in the various emphysema animal models.
In papain-induced emphysema, dissolution of collagen
fibrils is seen shortly after instillation of the enzyme [20].
Similarly, collagen is rapidly degraded in elastase-induced
emphysema [21] and studies have shown that short expo-
sure to toxic amounts of oxygen in rats will lead to emphy-
sematous changes and collagen degradation with no
changes in elastin [22].
The importance of collagen in this disease was raised
when it was shown that a transgenic mouse line that
expressed human MMP-1 (collagenase) in the lung devel-
oped emphysema with no effect on lung elastin content
[23]. This was the first time that it was shown that emphy-
sema could occur via an elastin-independent mechanism
and it has led to a shift from thinking of emphysema as
solely a disease of elastin degradation to one that incorpo-
rates collagen into the disease paradigm. The presence of
collagen adds tensile strength to the lung tissue and
allows the lung to maintain the structure needed to carry
out the physiologic function of gas exchange. Collagen
fibrils support this function by maintaining alveolar interde-
pendence in the lungs, thereby helping to preserve the
stability of small pulmonary airspaces. It is not surprising,Respiratory Research    Vol 2 No 6 Foronjy and D’Armiento
therefore, that damage to collagen fibrils may upset the
balance of forces in the lung and lead to the development
of overextended, emphysematous-appearing alveoli.
Studies examining collagen content in emphysematous
lungs have yielded conflicting results. While we have
demonstrated in the transgenic mouse model that the
development of emphysema was associated with a loss of
collagen without elastin degradation [23], other investiga-
tors have reported that the amount of collagen was actu-
ally increased in the septal regions of emphysematous
patients [15,24]. This may reflect the fact that matrix
remodeling is a dynamic process, with collagen degrada-
tion followed by repair ultimately increasing collagen
deposition in the lung. It may seem counterintuitive that
collagen content would be increased in a disease that is
characterized by the destruction and dilation of small air-
spaces in the lung. By means of alveolar interdependence,
however, increased collagen deposition in certain alveoli
could expose surrounding alveoli to potentially deleterious
forces of distension. If an alveolus in the earlier stage of
emphysema is surrounded by alveoli that are in the post-
repair phase, the effects may be even more exaggerated.
Increased collagenase in emphysema
Over the past several years, additional studies have
emerged to implicate collagenase and collagen break-
down in this disease process. Wright and Churg exposed
guinea pigs to cigarette smoke and demonstrated that the
development of emphysema was associated with morpho-
metric evidence of collagen breakdown and repair [25].
Following these findings, Selman and colleagues [26]
demonstrated that smoke exposure in guinea pigs caused
increased expression of collagenase and enhanced col-
lagenolytic activity within their lungs. In situ hybridization
showed that the collagenase expression was localized to
alveolar macrophages, epithelial cells and fibroblasts. This
increased collagenase activity was associated with a sig-
nificant decrease in the lung collagen concentration in the
smoke-exposed guinea pigs. These studies suggest that
collagenase is involved in the pathogenesis of emphysema
in animal models.
Recently, studies in humans have also demonstrated a
role for collagenase in emphysema patients. Finlay and
colleagues [12] showed that alveolar macrophages from
the bronchoalveolar lavage of emphysema patients had
augmented production of collagenase compared to
matched controls. Ohnishi et al. reported a significant
increase in collagenolytic activity within the lung
parenchyma of emphysema patients [13]. More recently,
our laboratory demonstrated the presence of MMP-1
mRNA, protein and collagenase activity within the lung
parenchyma of patients with emphysema when compared
to normal controls [27]. In this study, lung samples were
examined from 23 patients with emphysema undergoing
lung reduction surgery or lung transplantation. All but two
of the patients had stopped smoking. When immunolocal-
ization studies were performed on these samples the type
II pneumocyte was identified as the cell type producing
collagenase [27].
Other investigators have provided affirmative evidence for
the presence of MMP-1 in the lung parenchyma of emphy-
sema patients. Segura-Valdez et al. examined lung tissue
from 10 COPD patients and found increased expression
of collagenases 1, 2 and 3 [28]. Immunohistochemical
analysis also revealed that MMP-1 was found to be
present in alveolar and interstitial macrophages, endothe-
lial cells and epithelial cells from COPD patients. The
emerging data, while not conclusive, appears to point to a
significant presence of collagenase in the lung
parenchyma of patients with emphysema. These studies
introduce the concept that cells other then inflammatory
cells may participate in the destruction of the lung in
emphysema.
Conclusion
Our scope of understanding of the basic pathophysiol-
ogy of emphysema has advanced significantly in the past
decade. It is becoming increasingly evident that elastin
degradation alone cannot explain the morphological
changes that occur in smoking-induced emphysema. The
macrophage, which is the predominant cell in the
airways and alveolar spaces of emphysema patients,
contains an array of enzymes capable of digesting both
fibrillar collagen (MMP-1, MT1-MMP, MMP-13) and
elastin (MMP-9, MMP-12 and cathepsins). Of these,
MMP-1 and MMP-9 have been most consistently demon-
strated in the lungs of COPD patients. It is likely that cig-
arette smoke mediates its destructive changes through
both alterations in collagen and elastin. The disease
model set forth is outlined in Fig. 1. Cigarette smoke
leads to the recruitment of macrophages into the lung.
These macrophages secrete cytokines which further
augment the inflammatory response, leading to the
induction and release of proteolytic enzymes by
macrophages and neutrophils. This proteolytic cascade
leads to both collagen and elastin degradation. The
macrophages and cigarette smoke then stimulate the
parenchymal lung cells in patients susceptible to emphy-
sema to produce proteolytic enzymes. This results in a
significant imbalance of collagenase leading to altered
fibril arrangement. The initial damage is followed subse-
quently by a repair process that may result in increased
collagen deposition in the lung. These structural
changes alter the balance of opposing forces in the lung
and lead to the pathology of emphysema. The specific
molecular changes, which occur in the parenchymal lung
cells in response to cigarette smoke and inflammatory
cytokines, will be the focus of future studies investigating
the pathogenesis of emphysema.Much work lies ahead to define the role of collagenase in
the development of emphysema more clearly. Future
experiments will need to identify the factors that regulate
protease production within the pneumocyte and may
explain why only 10–20% of smokers develop emphy-
sema. As newer and more efficacious MMP inhibitors are
developed, it is conceivable that these agents may be uti-
lized in the future to halt the destructive changes associ-
ated with this disease. Given the tremendous economic,
physical and emotional toll that this disease inflicts, it is
imperative that research into understanding and treating
emphysema is supported. It is only through such efforts
that specific therapies for emphysema will be developed.
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Figure 1
Proposed proteolytic cascade in emphysema. (a) The exposure to cigarette smoke leads to recruitment of macrophages into the lung.
Macrophages secrete cytokines which further augment the inflammatory response leading to the induction and release of proteolytic enzymes by
macrophages and neutrophils, including matrix metalloproteinases (MMPs ) (MMP-1, -2, -8, -9, -12 and membrane type matrix metalloproteinase-1
[MT1-MMP]), inhibitors (tissue inhibitor of matrix metalloproteinase [TIMP-1]) and neutrophil elastase, that lead to the remodeling of the lung
architecture. This proteolytic cascade leads to both collagen and elastin degradation. The cigarette smoke exposure and inflammatory cells also
stimulate the lung parenchymal epithelial cells to secrete proteolytic enzymes which contribute to the destructive process in emphysema. The
macrophages and cigarette smoke then stimulate the parenchymal lung cells in patients susceptible to emphysema to produce proteolytic enzymes
which results in a significant imbalance of collagenase leading to altered fibril arrangement. The initial damage is followed subsequently by a repair
process in which fibroblasts participate inremodeling the collagen matrix of the lung. These structural changes alter the balance of opposing forces
in the lung and lead to the pathology of emphysema. (b) Disruption of the extracellular matrix (ECM) content by proteolysis upsets the balanced
forces within the lung and leads to alterations in alveolar structure.Respiratory Research    Vol 2 No 6 Foronjy and D’Armiento
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